All News

Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT
Janet Pope Janetbirdope ( View Tweet)

Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️
Janet Pope Janetbirdope ( View Tweet)

Potential rheum board question...
True or False?
MUC5B is a promoter variant that can increase the risk for ILD in RA
Dr. A Palomaki - winner of #EULAR 2021 Abstr award #OP0007 @RheumNow https://t.co/6xKHgXSJ29
k dao KDAO2011 ( View Tweet)

The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj
Dr. Rachel Tate uptoTate ( View Tweet)

Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj
k dao KDAO2011 ( View Tweet)

What is your treat to target for lupus patients? #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)

ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)

The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)

Dr. Angioni et al characterize PsA clinical remission on a molecular level. c-FOS and CCD50 (YMER) appear to be two key genes. #EULAR2021 poster #POS0409 @RheumNow https://t.co/4lytsgjdzj https://t.co/ySjIXBHTA0
Links:
Dr. Rachel Tate uptoTate ( View Tweet)

Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smaller deltas between ASAS40 results in PBO vs nr-axSpA compared to axSpA vs PBO in MEASURE 2, PREVENT, COAST-V, COAST-X, RAPID, C-axSpAnd. Dr. Deodhar #EULAR2021 @RheumNow https://t.co/V8zlZdGltQ
Dr. Rachel Tate uptoTate ( View Tweet)

"50% of time spent in LLDAS = 50% less damage accrual"- Prof E Morand reviews data on low disease activity state in lupus https://t.co/FU3hPvuyRU
k dao KDAO2011 ( View Tweet)

Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow
👉SLEDAI=0
👉MD global<0.5
👉dsDNA, C3/C4 does not matter
👉prednisone <=5 mg/d, stable meds
👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
k dao KDAO2011 ( View Tweet)

Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar discusses differences in tx withdrawal/dose reduction(PBO) shown in RE-EMBARK, ABILITY-3, C-OPTIMISE. #EULAR2021 @RheumNow https://t.co/wVYsPYFLAi
Dr. Rachel Tate uptoTate ( View Tweet)

MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX
Janet Pope Janetbirdope ( View Tweet)

To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)

Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 @RheumNow https://t.co/OdlQvGyNfY
Dr. Rachel Tate uptoTate ( View Tweet)

Introducing EULAR's new name: 'European Alliance of Associations for Rheumatology' highlighting the importance of collaboration in the scientific community and bringing the patient’s voice across all bodies of work #EULAR2021 @rheumnow
k dao KDAO2011 ( View Tweet)

Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm
Janet Pope Janetbirdope ( View Tweet)

Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)

Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021
Janet Pope Janetbirdope ( View Tweet)